Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Complement Factor I Antibodies:
anti-Human Complement Factor I Antibodies:
anti-Rat (Rattus) Complement Factor I Antibodies:
Go to our pre-filtered search.
Human Monoclonal Complement Factor I Primary Antibody for IP, RIA - ABIN2473072
Hsiung, Barclay, Brandon, Sim, Porter: Purification of human C3b inactivator by monoclonal-antibody affinity chromatography. in The Biochemical journal 1982
Show all 2 Pubmed References
Human Monoclonal Complement Factor I Primary Antibody for Func, IHC (fro) - ABIN2473071
Ernberg: Studies on Epstein-Barr virus-associated antigens. in Annals of the New York Academy of Sciences 1975
Show all 2 Pubmed References
Factor I-mediated generation of activated C3 fragments in the circulation is a critical determinant for the development of MPGN2 associated with factor H (show CFH Antibodies) deficiency.
This study has revealed a significant genetic role for CFI-rs13104777 in acute anterior uveitis. This influence may be dependent on human leukocyte antigen (show HLADRB4 Antibodies) (HLA)-B27 (show MRAP Antibodies) and disease laterality.
An extremely rare, heterozygous mutation in the gene encoding CFI likely affecting splicing was associated for the first time with atypical hemolytic uremic syndrome.
this study illustrates the importance of early versus late diagnosis of CFI deficiency
This finding although rare does suggest that screening for chromosomal rearrangements affecting CFI should be undertaken in all aHUS patients particularly if the factor I level is unexplainably low.
Factor I binds C3b-Factor H (show CFH Antibodies) between Factor H (show CFH Antibodies) domains 2 and 3 and a reoriented C3b C-terminal domain and docks onto the first scissile bond, while stabilizing its catalytic domain for proteolytic activity.
Taken together, our data argue that multiple rare and ultra-rare alleles in CFI contribute to AMD (show AMD1 Antibodies) pathogenesis; they improve the precision of the assessment of the contribution of CFI to AMD (show AMD1 Antibodies)
Case Report: thrombotic microangiopathy with mutations in complement factor I and thrombomodulin (show THBD Antibodies).
Our results indicate that CFI polymorphisms are not significantly associated with VKH syndrome.
Patients with advanced atrophic AMD (show AMD1 Antibodies) carried these rare variants more frequently than patients with neovascular AMD (show AMD1 Antibodies) (11 of 93 [11.8%] vs 40 of 835 [4.8%]; P = .04).
Low FI levels are strongly associated with rare CFI variants and age-related macular degeneration.
This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this gene have been associated with a predisposition to atypical hemolytic uraemic syndrome, a disease characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with immmune deposits is another condition associated with mutation of this gene.
complement factor I
, I factor (complement)
, complement factor 1
, C3B/C4B inactivator
, Konglutinogen-activating factor
, complement component I
, complement control protein factor I
, complement factor I heavy chain
, light chain of factor I
, complement component 1